Compare MFM & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MFM | IPSC |
|---|---|---|
| Founded | 1986 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 218.1M | 189.7M |
| IPO Year | N/A | 2021 |
| Metric | MFM | IPSC |
|---|---|---|
| Price | $5.24 | $2.08 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $3.50 |
| AVG Volume (30 Days) | 88.3K | ★ 1.4M |
| Earning Date | 01-01-0001 | 03-12-2026 |
| Dividend Yield | ★ 4.08% | N/A |
| EPS Growth | N/A | ★ 91.30 |
| EPS | ★ 0.03 | N/A |
| Revenue | N/A | ★ $109,164,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $176.33 | ★ N/A |
| Revenue Growth | N/A | ★ 1556.76 |
| 52 Week Low | $4.94 | $0.34 |
| 52 Week High | $5.67 | $2.97 |
| Indicator | MFM | IPSC |
|---|---|---|
| Relative Strength Index (RSI) | 29.73 | 42.70 |
| Support Level | $5.25 | $0.49 |
| Resistance Level | $5.47 | $2.71 |
| Average True Range (ATR) | 0.05 | 0.26 |
| MACD | -0.02 | -0.07 |
| Stochastic Oscillator | 5.69 | 7.73 |
MFS Municipal Income Trust is a diversified closed-end management investment company. Its investment objective is to seek high current income exempt from federal income tax, but it may also consider capital appreciation. The fund invests a majority of its net assets, including assets attributable to preferred shares and borrowings for investment purposes, in municipal bonds.
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.